Veru/$VERU
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Veru
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
- Ticker
- $VERU
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 20
- Headquarters
- Miami, United States
- Website
- verupharma.com
Veru Metrics
BasicAdvanced
$36M
-
-$0.67
-1.16
-
Price and volume
Market cap
$36M
Beta
-1.16
52-week high
$7.33
52-week low
$2.04
Average daily volume
191K
Financial strength
Current ratio
4.423
Quick ratio
4.181
Long term debt to equity
0.067
Total debt to equity
0.095
Profitability
EBITDA (TTM)
-27.703
Management effectiveness
Return on assets (TTM)
-54.03%
Return on equity (TTM)
-64.54%
Valuation
Price to book
1.29
Price to tangible book (TTM)
1.7
Price to free cash flow (TTM)
-1.665
Free cash flow yield (TTM)
-60.07%
Free cash flow per share (TTM)
-1.286
Growth
Earnings per share change (TTM)
-69.92%
3-year earnings per share growth (CAGR)
-64.73%
10-year earnings per share growth (CAGR)
-2.92%
What the Analysts think about Veru
Analyst ratings (Buy, Hold, Sell) for Veru stock.
Analyst projections of the future price of Veru stock.
Veru Financial Performance
Revenues and expenses
Veru Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.